Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eyetech, Inc.

Latest From Eyetech, Inc.

Merck & Co. To Enter Ophthalmology With EyeBio Buyout

Veteran developers stay on to accelerate development of potential first-in-class drug to challenge Bayer/Regeneron’s Eylea and Roche’s Vabysmo in a deal worth up to $3bn.

Clinical Trials Commercial

Stock Watch: Intellia Edits Out The Competition

Exciting early results in gene editing contrast with issues around traditional gene therapies, including non-responders, safety and questions over the duration of efficacy.

Stock Watch Gene Therapy

Stock Watch: Regeneron’s Constellation of Ophthalmic Competition

The accepted commercial dynamics of a competitive indication in older patients can be disrupted by new entrants with improved profiles, lower priced biosimilar competition and (soon) Medicare price negotiations.

Stock Watch Ophthalmic

Stock Watch: Beware The Halo Effect Of Biopharma Leaders

Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.

Stock Watch Leadership
See All

Company Information